The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The future of precision medicine in MDS: genomic profiling and venetoclax-based strategies
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future of precision medicine in myelodysplastic syndromes (MDS), emphasizing the need for a patient-centered approach that accounts for the disease’s heterogeneity and complex biology. Dr Bataller also reviews the VERONA trial of hypomethylating agents (HMAs) plus venetoclax, noting that the study did not meet its primary endpoint, and future research should focus on identifying MDS subgroups most likely to benefit from this combination. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
